Drug Trial Radar · NCT04707768
Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
Last checked: Nov 20, 2026Latest source record: Jan 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
456
Actual
Start
Jun 18, 2021
Primary completion
Jan 6, 2023
Study completion Jan 30, 2023
Sponsor
- Lead sponsor
- Akebia TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be conducted to demonstrate the efficacy and safety of vadadustat administered three times weekly (TIW) compared to a long-acting erythropoiesis-stimulating agent (ESA) (Mircera®) for the maintenance treatment of anemia in hemodialysis participants.
Conditions
- Anemia Associated With Chronic Kidney Disease (CKD)
Interventions
VadadustatDrug
oral tablets
Mircera®Drug
intravenous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Evaluation Period (PEP) (Weeks 20 to 26)Time frame: Baseline; Weeks 20 to 26
Locations
58 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Huntsville, Alabama
Research Site
Phoenix, Arizona
Research Site
Pine Bluff, Arkansas
Research Site
El Centro, California
Research Site
Escondido, California
Research Site
Fresno, California
Research Site
Granada Hills, California
Research Site
Porterville, California
Research Site
San Diego, California
Research Site
Arvada, Colorado
Research Site
Denver, Colorado
Research Site
Hockessin, Delaware
Research Site
Bradenton, Florida
Research Site
Coral Gables, Florida
Research Site#1
Coral Springs, Florida
Research Site#2
Coral Springs, Florida
Research Site
Jacksonville, Florida
Research Site
Athens, Georgia
Research Site
Buford, Georgia
Research Site
Dalton, Georgia
Research Site
Macon, Georgia
Research Site
Nampa, Idaho
Research Site
Baton Rouge, Louisiana
Research Site
Shreveport, Louisiana
Research Site
Plymouth, Massachusetts
Research Site
Springfield, Massachusetts
Research Site
Kalamazoo, Michigan
Research Site
Rochester Hills, Michigan
Research Site
Saint Clair Shores, Michigan
Research Site
Brookhaven, Mississippi
Research Site
Columbus, Mississippi
Research Site
Tupelo, Mississippi
Research Site
North Platte, Nebraska
Research Site
Las Vegas, Nevada
Research Site
Reno, Nevada
Research Site
Portsmouth, New Hampshire
Research Site
Albuquerque, New Mexico
Research Site
Gallup, New Mexico
Research Site
Charlotte, North Carolina
Research Site
Durham, North Carolina
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.